ThinkEquity Upgrades Anadys Pharma (ANDS) to Buy
ThinkEquity upgrades Anadys Pharma (Nasdaq: ANDS) from Accumulate to Buy with a $6 price target.
For more analyst ratings on ANDS click here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
Related Categories
UpgradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
